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Abstract 
Introduction: Improved knowledge of retinoblastoma chemotherapy resistance is 
needed to raise treatment efficiency. The objective of this study was to test whether 
etoposide alters glucosyl-ceramide, ceramide, sphingosine and sphingosine-1-
phosphate (sphingosine-1-P) levels in parental retinoblastoma cells (WERI Rb1) or their 
etoposide-resistant subclones (WERI EtoR). 
Material and methods: WERI Rb1 and WERI EtoR were incubated with 400 ng/ml 
etoposide for 24 hours. Levels of glucosyl-ceramides, ceramides, sphingosine, 
sphingosine-1-P were detected by Q-TOF mass spectrometry. Statistical analysis was 
done by ANOVA followed by Tukey post-hoc test (p<0.05) 
The mRNA expressions of sphingolipid pathway enzymes in WERI Rb1, WERI EtoR and 
four human retinoblastoma tissue samples were analyzed by quantitative real time PCR. 
Results: Pathways enzymes mRNA expression confirmed similarities of human 
sphingolipid metabolism in both cell lines and tissue samples, but different relative 
expression. Significant up-regulation of sphingosine was seen in both cell lines 
(p<0.001). Only sphingosine-1-P up-regulation was significantly increased in WERI EtoR 
(p<0.01), but not in WERI Rb1 (p>0.2).  
Conclusion: Both cell lines upregulate pro-apoptotic sphingosine after etoposide 
incubation, but only WERI EtoR produces additional survival favorable sphingosine-1-P. 
These data may suggest a role of sphingosine-1-P in retinoblastoma chemotherapy 
resistance, although this seems not to be the only resistance mechanism. 
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Introduction  
Retinoblastoma is the most common malignant eye tumor of the childhood with a 
lethality rates that reaches up to 95% if left untreated (1, 2). Currently, the most effective 
treatment in retinoblastoma is the surgical removal/enucleation of the affected eye, with 
obvious disadvantages for the child (2). In bilateral involvement, chemotherapy is 
administered in order to facilitate partial tumor regression and size reduction, but 
chemotherapy resistance frequently leads all too often to limited efficiency (3-10). 
Therefore, new adjuvant therapy is needed to raise therapy efficiency in chemotherapy 
resistant retinoblastoma.  
Recent advances in research have elucidated a central role of sphingolipids in cellular 
apoptosis and survival signaling mechanisms (11). Of particular interest is the apoptotic 
effect of up-regulation of glucosyl-ceramide, ceramide, and sphingosine expression, 
whereas sphingosine-1-phosphate (sphingosine-1-P) upregulation induces cell survival 
(11) (see fig 1). The apoptotic effect of sphingolipids has been demonstrated in various 
tumors including stomach, lung and kidney cancer, non-Hodgkin-lymphoma, colon 
adenomacarcinoma, astrocytoma, glioblastoma, and breast cancer (12-21). 
Furthermore, glucosyl-ceramide, ceramide and sphingosine up-regulation has been 
associated with increased chemotherapy efficiency in in vitro and in vivo tumor models 
(22-24). In contrast, sphingosine-1-P down-regulation has been accompanied with 
increased chemotherapy efficiency in tumor cells (25-28).  
Therefore, we hypothesized, that chemotherapy treatment in resistant retinoblastoma 
cells induces sphingosine-1-P expression, thus reducing chemotherapy efficiency. The 
objective of this study was to test, whether etoposide alters the level of glucosyl-
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ceramide, ceramide, sphingosine, and sphingosine-1-P in parental retinoblastoma cells 
(WERI Rb1) or their etoposide-resistant subclone (WERI EtoR). 
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Methods 
Authentication verifications of WERI Rb cell lines 
DNA fingerprinting of both human WERI Rb cell lines was confirmed by carried out DNA 
profiling using 8 different and highly polymorphic short tandem repeat (STR) loci. 
Authentication verifications were done by Leibniz Institute DSMZ ± German Collection of 
Microorganisms and Cell Cultures (www.dsmz.de). Generated STR profiles of used cell 
lines showed a full match of the respective parental reference STR profiles as indicated 
by a search of the database of cell banks ATCC (USA), JCRB (Japan), RIKEN (Japan), 
KCLB (Korea) and DSMZ. Samples of WERI Rb1 and WERI EtoR were taken from 
authenticated cell cultures. 
Also, both WERI Rb cell lines were tested for presence of mitochondrial DNA sequences 
from rodent cells as mouse, rat, Chinese and Syrian hamster. Results revealed no 
detection of any mitochondrial sequences from mouse, rat or Chinese and Syrian 
hamster cells in the human samples at a detection limit of 1:105. The samples are derived 
of pure human cell cultures.  
 
WERI Rb1 and WERI Rb1 etoposide-resistant subclones (WERI EtoR) 
The retinoblastoma cell line WERI Rb1 and the etoposide-resistant WERI Rb1 (WERI 
EtoR) subclone were a courtesy of Dr. H. Stephan (University Hospital, Essen, 
Germany) (29). Both cell lines were cultivated in cell culture medium containing DMEM 
supplemented with 15% FBS, 4 mM L-glutamine, 50 mM ß-mercaptoethanol, 10 mg 
insulin/mL, and penicillin/streptomycin at 37 °C at 10% CO2 and 80% humidity (30). 
DAPI/propidium iodide assays to determine apoptosis/necrosis rate confirmed 
chemotherapy sensitivity of WERI Rb1, but resistance of WERI EtoR after 400 ng/ml 
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etoposide incubation for 24 hours (fig 2). 
 
Glucosyl-ceramide, ceramide, sphingosine and sphingosin-1-P quantification 
WERI Rb1 and WERI EtoR were incubated with DMEM supplemented with 400 ng/ml 
etoposide or vehicle control for 24 hours. Ceramides, sphingosine and S1P were 
extracted and quantified as recently described (31-33). Briefly, lipid extraction of cells 
was performed using C17-sphingosine, C17-S1P and C17-ceramide as internal 
standards. Sample analysis was carried out by rapid resolution LC-MS/MS using a 
QTOF 6530 mass spectrometer (Agilent Technologies, Waldbronn, Germany) operating 
in the positive ESI mode. The precursor ions of sphingosine (m/z 300.289,) C17-
sphingosine (m/z 286.274), S1P (m/z 380.256), C17-S1P (m/z 366.240), C16-ceramide 
(m/z 520.508) and C17-ceramide (m/z 534.524) were cleaved into the fragment ions of 
m/z 282.280 for sphingosine, m/z 268.264 for C17-sphingosine, m/z 264.270, m/z 
250.252 for S1P, m/z 264.270 for C17-S1P and m/z 264.270 for ceramides, 
respectively. Quantitation was performed with Mass Hunter Software. 
 
Quantitative PCR (RT-PCR) for sphingolipid enzyme miRNA in retinoblastoma 
samples and cell lines 
To confirm the expression of sphingolipid enzyme mRNA, we used tumor tissue from 
four anonymous diagnosed retinoblastoma patients after enucleation. Biodata have 
been summarized in tab 1. Ethic committee approval of Charité Universitätsmedizin 
(Berlin, Germany) was obtained and the study was conducted following the guidelines of 
the Helsinki declaration. To obtain mRNA, 5 x 106-1 x 107 sensitive WERI Rb1 (n=5) and 
resistant WERI EtoR cells (n=5) were snap frozen in liquid nitrogen and stored at -80°C 
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until RNA isolation. Total RNA was extracted from four different retinoblastoma tumor 
tissues. The Gene Elute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich, Munich, 
Germany) was useGIRUWRWDO51$H[WUDFWLRQIROORZLQJPDQXIDFWXUHU¶VLQVWUXFWLRQV3XULW\
and concentration of RNA was quantified in a BioSpectrometer (Eppendorf, Hamburg, 
Germany). For cDNA synthesis, 1 µg total RNA was reverse-transcribed to cDNA using 
the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Darmstadt, Germany). 
Quantitative Real-time PCR  
The gene expression levels in the samples were determined by reverse-transcription 
quantitative real-time PCR (RT-qPCR) using PowerUpTM SYBR Green chemistry 
(Thermo Fisher Scientific, UK). PCR primers for the genes of interest were designed 
using Primer-BLAST (34). Where possible, the primers spanned exons and all of PCR 
products were within the 136-150 bp size range. Primer sequences are listed in tab 2. 
Beta-2-microglobulin (B2M; NM_004048.2) was chosen as the reference gene for 
normalization purposes. 2.5 ng of cDNA was used per 10 ȝO57-qPCR with 500 nM of 
the sense and antisense primers and run on a StepOnePlus real-time PCR system 
(Applied Biosystems, UK). PCRs were carried out in triplicate per primer set per sample. 
The resultant cycle threshold values (CT) were used to obtain the delta CT ǻ&T=CT 
target gene ± CT B2M reference gene) for each sample. The normalized expression 
levels of the genes of interest were calculated as 2^(-ǻ&7.  
 
Statistical analysis 
Data are presented as mean ± SD and mean ± SEM unless otherwise stated. Statistical 
Analysis was done by ANOVA followed by a Tukey post-hoc test using Statistical 
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Software (V10.0, Statsoft, Tulsa, Ok, USA). P-values below 0.05 were considered 
statistically significant. 
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Results 
Retinoblastoma tissue biodata 
Four human retinoblDVWRPDSDWLHQWV¶VDPSOHVZHUH LQFOXGHG LQ WKLVVWXG\2QHSDWLHQW
had no treatment before enucleation, one had chemotherapy before, one had beam 
radiation before and one had combined chemotherapy/beam radiation before. Three 
patients experienced bilateral retinoblastoma and one patient only unilateral 
retinoblastoma. None of the four patients have been diagnosed with metastasis or had 
risk factors for metastasis. All data have been displayed in tab 1. 
  
Etoposide-induced upregulation of apoptotic sphingosine in WERI Rb1 and WERI 
EtoR 
WERI Rb1 vehicle control, WERI Rb1 400 ng/ml etoposide, WERI EtoR vehicle, and 
WERI EtoR 400 ng/ml etoposide were incubated with DMEM supplemented with 
etoposide or vehicle control and harvested after 24 hours. Levels for apoptotic glucosyl-
ceramide, ceramide and sphingosine were evaluated by mass spectroscopy for all 
treatment groups. Statistical significant upregulation of apoptotic sphingosine was seen 
after etoposide treatment in WERI Rb1 and WERI EtoR (p<0.01, fig 3 A, absolute 
values and SD values tab 3). Slight downregulation of ceramide and glu-ceramide were 
seen after etoposide treatment in WERI Rb1 and WERI EtoR, but this was only 
statistical significant for ceramide in WERI Rb1 after etoposide treatment (p<0.5; fig 3 B 
and D, absolute values and SD values tab 3). 
 
Etoposide-induced upregulation of survival favoring sphingosine-1-P only in 
etoposide resistant WERI EtoR 
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WERI Rb1 vehicle control, WERI Rb1 400 ng/ml etoposide, WERI EtoR vehicle, and 
WERI EtoR 400 ng/ml etoposide were incubated with DMEM supplemented with 
etoposide or vehicle control for 24 hours and were harvested. Levels for survival 
favoring sphingosine-1-P were evaluated by mass spectroscopy. Statistical significant 
upregulation of sphingosine-1-P was seen after etoposide treatment in therapy resistant 
WERI EtoR, but not in therapy sensitive WERI Rb1 (p<0.01, fig 3 C, absolute values 
and SD values tab 3) 
 
Quantitative sphingolipid enzyme expression in human retinoblastoma samples 
and in WERI Rb1 and WERI EtoR 
mRNA expression of sphingolipid metabolism enzymes was measured by quantitative 
PCR in four human retinoblastoma samples and in WERI Rb1 and WERI EtoR. Fig 4 
displays the relative expression of sphingosine kinase 1 (SPHK1), sphingosine kinase 2 
(SPHK2), sphingosphingosine-1-phosphate receptor 1 (S1P1), sphingosphingosine-1-
phosphat receptor 2 (S1P2), sphingosphingosine-1-phosphate receptor 3 (S1P3), 
sphingosphingosine-1-phosphate receptor 4 (S1P4), sphingosphingosine-1-phosphate 
receptor 5 (S1P5), sphingosphingosine-1-phosphate phosphatase 1 (SGPP1), 
sphingosphingosine-1-phosphate phosphatase 2 (SGPP2), ceramide synthase 1 
(LASS1), ceramide synthase 2 (LASS2), ceramide synthase 3 (LASS3), ceramide 
synthase 4 (LASS4), ceramide synthase 5 (LASS5), ceramide synthase 6 (LASS6), acid 
ceramidase 1 (ASAH1), acid ceramidase 2 (ASAH2), alkaline ceramidase 1 (ACER1), 
alkaline ceramidase 2 (ACER2), alkaline ceramidase 3 (ACER3), ceramide kinase 
(CERK), ceramide kinase like (CERKL), sphingomyelin synthase 1 (SGMS1), 
sphingomyelin synthase 2 (SGMS2), acid sphingomyelinase 1 (SMPD1), neutral 
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sphingosphingomyelinase 2 (SMPD2), neutral sphingomyelinase 3 (SMPD3), neutral 
sphingomyelinase 4 (SMPD4), alkaline sphingomyelinase  (ENPP7)). No expression or 
almost no expression has been detected for ACER1, ASAH2, ENPP7, S1P1 S1P4 and 
S1P5 in retinoblastoma tissue, WERI Rb1 and WERI EtoR. For ASAH1, CERK, LASS1, 
LASS2, LASS6, S1P3, SGPP1, SGPP2, SMPD2 and SPHK1 lowest expression was 
seen in retinoblastoma tissue and highest in WERI EtoR. 
Taken together, the similar sphingolipid enzyme mRNAs, and especially SPHK1 and 
SPHK2, are at all expressed in four human retinoblastoma samples and in WERI Rb1 
and WERI EtoR. Differences have been found between native tissue and both cell lines 
in relative expression of these enzymes. 
 13 
Discussion 
The objective of this study was to test, whether etoposide alters the level of glucosyl-
ceramide, ceramide, sphingosine, and sphingosine-1-P in parental retinoblastoma cells 
(WERI Rb1) or their etoposide-resistant subclone (WERI EtoR). Data from this study 
demonstrate significant upregulation of sphingosine expression following etoposide 
treatment in WERI Rb1 and WERI EtoR and therefore presume an apoptotic signal in 
both cell lines. Up-regulation of survival favoring sphingosine-1-P was only seen in 
therapy-resistant WERI EtoR following etoposide treatment, but not in chemotherapy-
sensitive WERI Rb1. Therefore, we assume a survival signal in WERI EtoR, which might 
explain etoposide-resistance. In accordance with the sphingosine data, small decrease 
in glucosyl-ceramide and ceramide levels was detected following etoposide therapy, 
which might be a result of a consumptive shift to sphingosine in WERI Rb1 and WERI 
EtoR. As etoposide-induced downregulation of apoptotic ceramide and at the same time 
cell death in WERI Rb1, this suggests that there might be other apoptotic mechanisms 
leading to etoposide-vulnerable WERI Rb1, which is not in  WERI EtoR. Taken together, 
these data may indicate a functional role of sphingosine-1-P in retinoblastoma 
chemotherapy resistance, but seems not to be the only resistance mechanism.  
Experiments to demonstrate sphingolipid differences following treatment were 
conducted with previously described etoposide-sensitive WERI Rb1 and etoposide-
resistant WERI EtoR (29). Key analysis of our study, measurements of sphingosine, 
sphingosine-1-P, glucosyl-ceramide and ceramide, were performed by Q-TOF mass 
spectrometry, as described before (31-33). Realizing the role of sphingolipid enzymes, 
and especially SPHK1 and SPHK2, in sphingosine-1-P chemotherapy resistance of 
different tumor cells, we investigated their mRNA expression in four human 
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retinoblastoma samples and in WERI Rb1 and WERI EtoR in this study. Therefore, we 
have not only seen upregulation of sphingosine-1-P in retinoblastoma chemotherapy-
resistant cells, but also demonstrated similarity of sphingolipid metabolism in the used 
WERI Rb1 and WERI EtoR cell models as well in human retinoblastoma tissue.  
Our results are consistent with findings from other study groups for sphingosine-1-P and 
SPHK1 and 2 in other diverse tumors. For example, SPHK1-siRNA-knockout 
experiments showed a reduction of sphingosine-1-P-levels and a reduced proliferation in 
prostatic tumor cells, pancreatic tumor cells and leukemia cells (25-28, 35). Furthermore, 
sphingosine-1-P expression upregulation was seen after treatment in daunorubicin-
resistant leukemia (28, 35). Interestingly, increased SPHK1 expression have been also 
demonstrated in human samples of stomach tumors, lung tumors, kidney tumors, non-
Hodgkin-lymphoma, colon carcinoma, astrocytoma, glioblastoma and breast cancer (12-
21). In particular, in breast cancer, high SPHK1 expression is associated with 
unfavorable prognosis (20, 21). Furthermore, in-vitro-SPHK1-overexpression leads to 
transformation of benign NIH3T3 fibroblasts into fibrosarcomas (36). This phenomenon 
is reversible after competitive SPHK1 inhibition with N,N¶-dimethyl-sphingosine (36). 
Moreover, SPHK1 expression levels are positive correlated with chemotherapy 
resistance in prostatic tumor cells, pancreatic tumor cells and leukemia cells (25-28). 
Also, increased doxorubicin-induced apoptosis rates are demonstrated in breast cancer, 
gliobastoma and colon tumor SPHK2-siRNA-knockout-celllines (16, 37). 
Further experiments manipulating sphingolipid metabolism enzymes in chemotherapy-
resistance retinoblastoma cells are planned in order to better understand the 
significance of sphingosine-1-P function in retinoblastoma chemotherapy resistance and 
chemotherapy vulnerability in these cells. 
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Fig 1 Schematic cascade of sphingolipid metabolism 
Three sphingolipids (glu-ceramide, ceramide, sphingosine) induce apoptosis, whereas 
sphingosine-1-P sends a survival signal. The figure involves the enzymes Glu-
Ceramide-Synthase (GCS) Glu-Ceramidase (GCS), Ceramide-Synthase (LASS), 
Ceramidase (ASAH), Sphingosinekinase (SPHK) and Sphingosinephosphatase (SGPP). 
The box below lists sphingosine-1-P-receptors. 
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Fig 2 DAPI/propidium iodide assays  
A) Assay example shows apoptosis/necrosis rate in retinoblastoma cells after etoposide 
treatment. The yellow arrow marks a propidium iodide positive necrotic cell. The white 
arrow marks a DAPI positive apoptotic cell. The green arrow marked a DAPI/propidium 
iodide negative, alive cell.  
B) Assay example shows a higher vulnerability of WERI Rb1 to etoposide (x axis: 
treatment group and vehicle control of each cell line; y axis: percentage of necrotic or 
apoptotic cells to all cells; n=5). Statistical significant differences and p-values are 
integrated in the figure. 
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Fig 3 Sphingolipid measurements 
Graphic shows statistical significant up-regulation of apoptotic sphingosine WERI-Rb1 
and etoposide-resistant WERI EtoR (A, p < 0,01), but only statistical significant up-
regulation of survival-favoring sphingosine-1-P in etoposide-resistant WERI EtoR (p < 
0,01). Further (A) small down-regulation of ceramide (B) and glu-ceramide (D) was seen 
in WERI Rb1 and WERI EtoR after etoposide treatment was seen both celll lines (p < 
0,05 for ceramide downregulation in WERI Rb1 after etoposide treatment, all other p > 
0,1). Treatment or vehicle group (WERI Rb1 or WERI EtoR) are on the x-axis and 
amount of sphingosine (A, pmol per mg protein), ceramide (B, nmol per mg protein), 
sphingosine-1-P (C, pmol per mg protein) and glu-ceramide (D, nmol per mg protein) are 
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on the y-axis. Mean values (mean), standard diviation values (SD) and standard error of 
the mean (SEM) has been shown as box plots. Statistical analysis was done by Anova 
with Tukeys post-test. P values < 0,05 has been marked with * and p values < 0,01 has 
been marked with **. 
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Fig. 4 Normalized gene expressions of proteins of the ceramide pathway in 
retinoblastoma tissue, WERI-Rb1 and WERI EtoR 
mRNAs with CT values above 40.0 are considered as not expressed (n.e.). 
Normalization was done using the expression of ß2-microglobulin as reference. 
Expression levels are calculated from RT-qPCR ǻ&T means as 2(-ǻ&7. Statistical 
analysis was done by Anova with Tukeys post-test. p values < 0.05 are set as significant 
(*); p < 0.01 as **, p < 0.001 as ***.  
 
 
 26 
 
patient 
clinical TNM 
classification 
pathological 
TNM 
classification age histology previous treatment 
unilateral/
bilateral 
isolated/ 
heritable risk factors 
1 ycTxNxMxRxLxVx ypT1NxMXRxLxVx 2m endophytic non bilateral unknown none 
2 ycT1NxMxRxLxVx ypT1NxMXRxLxVx 6y 6m exophytic 
5 cycles 
chemotherapy bilateral isolated none 
3 ycT1NxMxRxLxVx ypT1NxMXRxLxVx 1y 8m exophytic 
7 cycles 
chemotherapy       
external beam 
radiotherapy bilateral unknown none 
4 ycT2NxMxRxLxVx ypT1NxMXRxLxVx 6y 5m endophytic 
external beam 
radiotherapy unknown unknown none 
 
Tab. 1 Clinical and histopathological features of the four patients with 
retinoblastoma 
Clinical and pathological TNM classification, age, histology, previous treatment, previous 
treatment, unilateral or bilateral cases, isolated or heritable, and risk factors for 
metastasis have been listed. 
 
 
 27 
 
Sequence Name Sequence 
LASS1_FOR GTACATCGTGGCGTTTGCAG 
LASS1_REV AAGCGCTTGTCCTTCACCAG 
LASS2_FOR AGCCCAAGCAGGTGGAAGTA 
LASS2_REV ATCTCCAGCTGGCTTCTCGG 
LASS3_FOR GGAAGCTTGCTGGAGATTTGC 
LASS3_REV CAGTACTGGGATGGCAGCAG 
LASS4_FOR CGTGGAGGAAGAGGCATTGAG 
LASS4_REV TGTCCACGTGACATTGGGTG 
LASS5_FOR GGTTTCGCCATCGGAGGAAT 
LASS5_REV TGTCGGATGTCCCAGAACCA 
LASS6_FOR GCGCCATAGCCCTCAACATT 
LASS6_REV CCCAGTCCAGTTGCTTGGAG 
SGPP1_FOR TCTTATTCCCTGCTGGTGTTCTC 
SGPP1_REV GTTGAAGTTGTCAATCAGGTCCAC 
SGPP2_FOR CATACGGTCCTGGATGTGCTG 
SGPP2_REV TGGCACAACTATGACACACACG 
SGMS1_FOR TTCAGCGACTGAAGGAGTGTG 
SGMS1_REV TGGTGTGCCTGAATCATGCTG 
SGMS2_FOR CTCTACCTGTGCCTGGAATGC 
SGMS2_REV CGCTGAAGAGGAAGTCTCCAC 
SMPD1_FOR TGGCTGCTCAGTTCTTTGGC 
SMPD1_REV TGGTACACACGGTAACCAGGA 
SMPD2_FOR TTTGCTGGAGGAGGTGTGGAG 
SMPD2_REV AAGCTCCTGGATTGGATGTTTGG 
SMPD3_FOR GTGTAACGACGATGCCCTGG 
SMPD3_REV GGATGGCGCTGTCCTCTTG 
SMPD4_FOR GGGGCGGTACCAGATCATCA 
SMPD4_REV TGTGGTTGATGGCAGACGAC 
ENPP7_FOR TGCTGCACACAGAATCTGCTC 
ENPP7_REV GGCGTTATGCGACCTCAGAC 
ASAH1_FOR CTGTCCTCAACAAGCTGACCG 
ASAH1_REV TGTCTCAGAGGCCGCATTCT 
ASAH2_FOR GGGCCATTTGTAGCAGCCTT 
ASAH2_REV AATGCACATGCTAGGCCCAC 
ACER1_FOR GTGGACTGGTGTGAGAGCAAC 
ACER1_REV ACGTAAATGTAGCGGGAGCG 
ACER2_FOR GTGTCCTGTCTGCGGTTACG 
ACER2_REV AGGCCCAGCTTAAACACACG 
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ACER3_FOR CCGAGTTCTGGAATACAGTGAGTAA 
ACER3_REV GAAGCACCAGGATCCCATTCC 
CERK_FOR CTGCACGGTCTGATTGGGAG 
CERK_REV CCACGGTGGAGTAACACACG 
CERKL_FOR TCGATGGATGTCCCCTAACCA 
CERKL_REV TCCCTGTGCCCTCCTTTCTT 
SPHK1_FOR TGGCTGAGGCTGAAATCTCCT 
SPHK1_REV CGTTCACCACCTCGTGCAT 
SPHK2_FOR TTCCGGAAGAAAGGGATCTGGG 
SPHK2_REV GACCTTCAGCTCTCCAACACTG 
S1P1_FOR TGAGCGAGGCTGCGGTT 
S1P1_REV CGCTACTCCAGACGAACGCTA 
S1P2_FOR GCCTAGCCAGTTCTGAAAGCC 
S1P2_REV GAGGTCGTCTCCTGCGTTTC 
S1P3_FOR GACGGAGGAGCCCTTTTTCAAC 
S1P3_REV GGCATTCACAGACGATTAGCTCC 
S1P4_FOR CGCGACGCTGGGTCTACTAT 
S1P4_REV CCCTCCCGTAGGAACCACTG 
S1P5_FOR CTCACTCGGTTCAAGGCAGC 
S1P5_REV GGAGCTTGCCGGTGTAGTTG 
B2M_FOR CTACACTGAATTCACCCCCACTG 
B2M_REV AATGCGGCATCTTCAAACCTCC 
 
 
Tab. 2 Quantitative Real-time PCR primer for sphingolipid enzymes 
PCR primer sequences used for quantitative PCR of sphingolipid gene expression: 
sphingosine kinase 1 (SPHK1), sphingosine kinase 2 (SPHK2), sphingosphingosine-1-
phosphate receptor 1 (S1P1), sphingosphingosine-1-phosphat receptor 2 (S1P2), 
sphingosphingosine-1-phosphate receptor 3 (S1P3), sphingosphingosine-1-phosphate 
receptor 4 (S1P4), sphingosphingosine-1-phosphate receptor 5 (S1P5), 
sphingosphingosine-1-phosphate phosphatase 1 (SGPP1), sphingosphingosine-1-
phosphate phosphatase 2 (SGPP2), Ceramide synthase 1 (LASS1), ceramide synthase 
2 (LASS2), ceramide synthase 3 (LASS3), ceramide synthase 4 (LASS4), ceramide 
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synthase 5 (LASS5), ceramide synthase 6 (LASS6), acid ceramidase 1 (ASAH1), acid 
ceramidase 2 (ASAH2), alkaline ceramidase 1 (ACER1), alkaline ceramidase 2 
(ACER2), alkaline ceramidase 3 (ACER3), ceramide kinase (CERK), ceramide kinase 
like (CERKL), sphingomyelin synthase 1 (SGMS1), sphingomyelin synthase 2 (SGMS2), 
acid sphingomyelinase 1 (SMPD1), neutral sphingomyelinase 2 (SMPD2), neutral 
sphingomyelinase 3 (SMPD3), neutral sphingomyelinase 4 (SMPD4), alkaline 
sphingomyelinase (ENPP7). 
 
 30 
 
sphingolipids WERI RB ETOR Vehicle 
WERI RB ETOR 
Etoposid WERI Normal Vehicle 
WERI Normal 
Etoposid 
nmol Glu-ceramide  
/mg Protein 26,77 (+/-20,54) 21,1 (+/-10,43) 52,56 (+/-41,40) 26,45 (+/-18,89) 
nmol ceramide  
/mg Protein 15,22 (+/-10,90206) 11,95 (+/-5,45785) 26,95 (+/-16,8696) 13 (+/-6,87694) 
nmol sphingosine  
/mg Protein 0,12 (+/-0,03) 0,54 (+/-0,16) 0,11  (+/-0,02) 0,48142  (+/-0,13) 
nmol sphingosine-1-P 
/mg Protein 0,05 (+/-0,02) 0,1 (+/-0,06) 0,08 (+/-0,06) 0,11 (+/-0,07) 
 
 
Tab. 3 Absolute Sphingolipid values 
Absolute values of sphingosine, ceramide, sphingosin-1-P and, Glucosyl-ceramide for 
each treatment group (WERI Rb1 vehicle, WERI Rb1 etoposide, WERI EtoR vehicle, 
WERI EtoR etoposide) were given in nmol per mg total protein. 
 
